NCT04537884View on ClinicalTrials.gov

Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 8, 2020

Primary Completion Date

January 25, 2022

Study Completion Date

January 25, 2022

Conditions

Diabetic Macular EdemaNeovascular Age-related Macular Degeneration

Interventions

DRUG

UBX1325

Investigational drug intravitreal injection

Trial Locations (8)

33143

MedEye Associates, Miami

33880

Center for Retina and Macular Disease, Winter Haven

34239

Sarasota Retina Institute, Sarasota

46290

MidWest Eye Institute, Indianapolis

77025

Houston Eye Associates, Houston

78240

Medical Center Ophthalmology Associates, San Antonio

90211

Retina-Vitreous Associates Medical Group, Beverly Hills

92647

Salehi Retina Institute, Huntington Beach

All Listed Sponsors

lead

Unity Biotechnology, Inc.

INDUSTRY

NCT04537884 - Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration | Biotech Hunter | Biotech Hunter